Javier Ampuero1, José A Del Campo1, Lourdes Rojas1, José R García-Lozano2, Ricard Solá3, Raúl Andrade4, José A Pons5, José M Navarro6, José L Calleja7, María Buti8, María F González-Escribano9, Xavier Forns8, Moisés Diago10, Javier García-Samaniego11, Manuel Romero-Gómez1. 1. Unit for Clinical Management of Digestive Diseases and ciberehd, Valme University Hospital, Sevilla, Spain. 2. Immunology Unit, Virgen del Rocio Hospital, Sevilla, Spain. ‡ Mar Hospital, Barcelona, Spain. 3. Mar Hospital, Barcelona, Spain. 4. Digestive Unit and ciberehd. Virgen de la Victoria University Hospital, Málaga, Spain. 5. Virgen de la Arraixaca University Hospital, Murcia, Spain. 6. Costa del Sol Hospital, Marbella, Spain. 7. Puerta de Hierro Hospital, Madrid, Spain. 8. Hepatology Unit and ciberehd. Vall d'Hebrón Hospital, Barcelona, Spain. 9. Immunology Unit, Virgen del Rocio Hospital, Sevilla, Spain. 10. Digestive Department, Valencia Hospital, Spain. 11. Digestive Unit and ciberehd. Carlos III Hospital, Madrid, Spain.
Abstract
BACKGROUND: Hepatitis C virus (HCV) is associated with a higher prevalence of steatosis compared to the general population. AIM: Our aim was to assess the impact of PNPLA3 rs738409 G-allele on steatosis in HCV patients. MATERIAL AND METHODS: We included 474 HCV patients treated with peginterferon plus ribavirin. PNPLA3 rs738409 was genotyped and patients were classified according to alleles and genotypes. Steatosis was detected in 46.4% (220/474). Fibrosis was assessed by Scheuer score. Gene expression was analyzed in Huh7.5 and Huh7 cells using Real Time-PCR. RESULTS: PNPLA3 allele-G was associated with steatosis [54.1% (126/233) vs. 39% (94/241)] (p = 0.0001). In HCV-1, allele-G was related to steatosis [50.6% (82/162) vs. 32.3% (53/164)] (p = 0.001), but did not in HCV-3 [61.9% (26/42) vs. 62% (31/50)] (p = 0.993). PNPLA3 allele-G was associated with steatosis in patients with IL28B-CT/TT [57.7% (82/142) vs. 37.1% (56/151)] (p = 0.0001), but did not in IL28B-CC [47.8% (43/90) vs. 42% (37/88)] (p = 0.442). Independent variables associated with steatosis were: PNPLA3 G-allele [O.R. 1.84 (CI95%: 1.06-3.21); p = 0.007], age [O.R. 1.04 (CI95%: 1.01-1.07); p = 0.017], HCV-genotype 3 [O.R. 2.46 (CI95%: 1.30-4.65); p = 0.006], HOMA > 4 [O.R. 2.72 (CI95%: 1.27-5.82); p = 0.010]. Since PNPLA3 RNA could not be detected on PBMC from HCV patients, an in vitro analysis was performed. Huh7.5 cells infected with JFH1 had a decreased PNPLA3 gene expression (fold inhibition = 3.2 ± 0.2), while Huh7 cells presented increased PNPLA3 gene expression (fold induction = 1.5 ± 0.2). CONCLUSION: PNPLA3 allele-G modulated the development of steatosis, particularly in patients with HCV-1 and IL28B-CT/TT genotype, but was not associated with SVR. Metabolic but not viral steatosis seems to be PNPLA3 regulated. Gene interaction may result in differential PNPLA3 gene expression levels in HCV infection.
BACKGROUND:Hepatitis C virus (HCV) is associated with a higher prevalence of steatosis compared to the general population. AIM: Our aim was to assess the impact of PNPLA3rs738409 G-allele on steatosis in HCVpatients. MATERIAL AND METHODS: We included 474 HCVpatients treated with peginterferon plus ribavirin. PNPLA3rs738409 was genotyped and patients were classified according to alleles and genotypes. Steatosis was detected in 46.4% (220/474). Fibrosis was assessed by Scheuer score. Gene expression was analyzed in Huh7.5 and Huh7 cells using Real Time-PCR. RESULTS:PNPLA3 allele-G was associated with steatosis [54.1% (126/233) vs. 39% (94/241)] (p = 0.0001). In HCV-1, allele-G was related to steatosis [50.6% (82/162) vs. 32.3% (53/164)] (p = 0.001), but did not in HCV-3 [61.9% (26/42) vs. 62% (31/50)] (p = 0.993). PNPLA3 allele-G was associated with steatosis in patients with IL28B-CT/TT [57.7% (82/142) vs. 37.1% (56/151)] (p = 0.0001), but did not in IL28B-CC [47.8% (43/90) vs. 42% (37/88)] (p = 0.442). Independent variables associated with steatosis were: PNPLA3 G-allele [O.R. 1.84 (CI95%: 1.06-3.21); p = 0.007], age [O.R. 1.04 (CI95%: 1.01-1.07); p = 0.017], HCV-genotype 3 [O.R. 2.46 (CI95%: 1.30-4.65); p = 0.006], HOMA > 4 [O.R. 2.72 (CI95%: 1.27-5.82); p = 0.010]. Since PNPLA3 RNA could not be detected on PBMC from HCVpatients, an in vitro analysis was performed. Huh7.5 cells infected with JFH1 had a decreased PNPLA3 gene expression (fold inhibition = 3.2 ± 0.2), while Huh7 cells presented increased PNPLA3 gene expression (fold induction = 1.5 ± 0.2). CONCLUSION:PNPLA3 allele-G modulated the development of steatosis, particularly in patients with HCV-1 and IL28B-CT/TT genotype, but was not associated with SVR. Metabolic but not viral steatosis seems to be PNPLA3 regulated. Gene interaction may result in differential PNPLA3 gene expression levels in HCV infection.
Authors: Charlotte J Green; Deborah Johnson; Harsh D Amin; Pamela Sivathondan; Michael A Silva; Lai Mun Wang; Lara Stevanato; Catriona A McNeil; Erik A Miljan; John D Sinden; Karl J Morten; Leanne Hodson Journal: Am J Physiol Endocrinol Metab Date: 2015-06-30 Impact factor: 4.310
Authors: Beatriz Mateos-Muñoz; Elena García-Martín; María J Torrejón; María J Devesa-Medina; Gara Esguevillas; María C Cárdenas; Cristina Fernández; Miguel Carballo; José A Agúndez; José M Ladero Journal: Medicine (Baltimore) Date: 2016-03 Impact factor: 1.889
Authors: Habeeb Salameh; Maen Masadeh; Muhannad Al Hanayneh; Vincent Petros; Matthew Maslonka; Arjun Nanda; Ashwani K Singal Journal: World J Hepatol Date: 2016-12-18
Authors: Bernhard Scheiner; Mattias Mandorfer; Philipp Schwabl; Berit Anna Payer; Theresa Bucsics; Simona Bota; Maximilian C Aichelburg; Katharina Grabmeier-Pfistershammer; Albert Stättermayer; Peter Ferenci; Michael Trauner; Markus Peck-Radosavljevic; Thomas Reiberger Journal: PLoS One Date: 2015-11-23 Impact factor: 3.240